Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2958740 | 0.87 | ALDH1A1 (0.38) | ALDH1A1KDM4EMEN1NPC1GAA | |
| SCHEMBL2963789 | 0.85 | MAPK1 (0.36) | ALDH1A1MEN1NPC1MAPTRAB9A | |
| SCHEMBL2967669 | 0.79 | RAPGEF4 (0.34) | ALDH1A1NPSR1MAPK1 | |
| SCHEMBL2974124 | 0.79 | NPC1 (0.41) | ALDH1A1NPC1GAAMAPTRAB9A | |
| SCHEMBL2973021 | 0.75 | ALDH1A1 (0.35) | ALDH1A1MAPK1 | |
| SCHEMBL2973544 | 0.74 | MAPK1 (0.33) | ALDH1A1KDM4EMAPK1 | |
| SCHEMBL2975438 | 0.72 | ALDH1A1 (0.36) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL2957337 | 0.72 | NPC1 (0.35) | ALDH1A1KDM4EMEN1NPC1GAA | |
| SCHEMBL2968937 | 0.71 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL2971361 | 0.69 | ALDH1A1 (0.39) | ALDH1A1KDM4EMEN1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | ALDH1A1 4332/4885KDM4E 2177/4885MEN1 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.